48,390 Shares of AstraZeneca Plc $AZN Purchased by Lido Advisors LLC

Lido Advisors LLC purchased a new position in AstraZeneca Plc (NYSE:AZN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,390 shares of the company’s stock, valued at approximately $7,814,000.

Other hedge funds also recently modified their holdings of the company. Gen Wealth Partners Inc bought a new position in AstraZeneca in the third quarter valued at approximately $155,000. Alpha Family Trust acquired a new position in shares of AstraZeneca in the third quarter valued at approximately $181,000. AEGON ASSET MANAGEMENT UK Plc increased its position in shares of AstraZeneca by 2.2% during the third quarter. AEGON ASSET MANAGEMENT UK Plc now owns 1,947,801 shares of the company’s stock worth $317,752,000 after acquiring an additional 42,690 shares in the last quarter. M&G PLC increased its position in shares of AstraZeneca by 14.3% during the third quarter. M&G PLC now owns 5,125,209 shares of the company’s stock worth $801,675,000 after acquiring an additional 642,497 shares in the last quarter. Finally, AlphaCore Capital LLC increased its position in shares of AstraZeneca by 78.1% during the third quarter. AlphaCore Capital LLC now owns 7,656 shares of the company’s stock worth $1,239,000 after acquiring an additional 3,357 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Nordea Equity Research upgraded shares of AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Royal Bank Of Canada started coverage on AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating for the company. Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.

AstraZeneca Price Performance

Shares of AZN opened at $184.46 on Friday. The stock has a market capitalization of $286.08 billion, a P/E ratio of 26.09, a P/E/G ratio of 1.44 and a beta of 0.24. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71. The company has a 50 day moving average of $168.42 and a 200-day moving average of $180.21. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The firm had revenue of $16.21 billion for the quarter, compared to analysts’ expectations of $16 billion. During the same period in the previous year, the firm posted $2.38 EPS. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. As a group, equities research analysts forecast that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.